Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high‐risk hematopoietic cell transplant recipients

Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study

(2021) Léna Royston et al.   Vaccines

Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection

(2020) Irene Cassaniti et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation

(2019) Francisco M. Marty et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

(2017) Francisco M. Marty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.

(2016) Per Ljungman et al.   CLINICAL INFECTIOUS DISEASES

The role of cytomegalovirus serostatus on outcome of hematopoietic stem cell transplantation

(2014) Per Ljungman   CURRENT OPINION IN HEMATOLOGY

The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase

(2011) T. Goldner et al.   JOURNAL OF VIROLOGY

Evidence for a Bidirectional Relationship between Cytomegalovirus Replication and acute Graft-versus-Host Disease

(2010) Nathan Cantoni et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Prospective comparison of PCR-based vs late mRNA-based preemptive antiviral therapy for HCMV infection in patients after allo-SCT

(2010) H Hebart et al.   BONE MARROW TRANSPLANTATION

Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective

(2009) Marcie Tomblyn et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION